Debjani Sahni, MBBS
Dr. G. Robert Baler Junior Faculty Professor, Dermatology
Biography
Dr. Sahni joined the BUSM faculty as an instructor of Dermatology and staff dermatologist at Boston Medical Center in 2011. She was promoted to assistant professor in 2012 and serves as director of the multi-disciplinary Cutaneous Oncology Program. She specializes in the care of cutaneous oncology patients, including cutaneous lymphomas and the medical management of melanoma and high-risk non-melanoma skin cancers. Dr. Sahni also directs the Cutaneous Oncology Fellowship and the International Program in Dermatology (IGPD). First established in 1988, the IGPD offers international postgraduate doctors the opportunity to train in dermatology, utilizing state-of-the-art facilities and therapies available in the US. Dr. Sahni’s clinical research interests focus on the epidemiology and treatment of skin cancers. She is a member of the Medical Advisory Council for the Cutaneous Lymphoma Foundation. Her academic interests include teaching and mentoring. She has lectured both in Europe and the US, and is the author of a number of scientific papers. Since her arrival seven years ago, she has received four Department of Dermatology Teacher of the Year awards. Dr. Sahni received her MBBS from the United Medical and Dental Schools of Guy’s and St Thomas’ Hospitals in London. After finishing her internal medicine residency she acquired her MRCP (Membership of the Royal College of Physicians) and completed a dermatology residency at the St John’s Institute of Dermatology in London followed by a cutaneous oncology fellowship at Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston.
Other Positions
- Director, Cutaneous Oncology, Dermatology, Boston University Chobanian & Avedisian School of Medicine
Education
- King's College London, MBBS
- King's College London, BSc
Classes Taught
- MEDDM822
- MEDDM852
- MEDDM872
- MEDDM901
- MEDDM902
Publications
- Published on 7/3/2023
Kennamer B, Sachedina D, Nagrani N, Brem C, Sahni D. A Rare Case of Anetodermic Mycosis Fungoides. Acta Derm Venereol. 2023 Jul 03; 103:adv11926. PMID: 37395580.
Read at: PubMed - Published on 5/1/2023
Kashani-Sabet M, Leachman SA, Stein JA, Arbiser JL, Berry EG, Celebi JT, Curiel-Lewandrowski C, Ferris LK, Grant-Kels JM, Grossman D, Kulkarni RP, Marchetti MA, Nelson KC, Polsky D, Seiverling EV, Swetter SM, Tsao H, Verdieck-Devlaeminck A, Wei ML, Bar A, Bartlett EK, Bolognia JL, Bowles TL, Cha KB, Chu EY, Hartman RI, Hawryluk EB, Jampel RM, Karapetyan L, Kheterpal M, Lawson DH, Leming PD, Liebman TN, Ming ME, Sahni D, Savory SA, Shaikh SS, Sober AJ, Sondak VK, Spaccarelli N, Usatine RP, Venna S, Kirkwood JM. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023 May 01; 159(5):545-553. PMID: 36920356.
Read at: PubMed - Published on 5/5/2020
Sanchez DP, Maymone MBC, McLean EO, Kennedy KF, Sahni D, Secemsky EA, Vashi NA. Racial and ethnic disparities in melanoma awareness: A cross-sectional survey. J Am Acad Dermatol. 2020 Oct; 83(4):1098-1103. PMID: 32380221.
Read at: PubMed - Published on 11/14/2019
Al-Haseni A, Vrable A, Qureshi MM, Mathews S, Pollock S, Truong MT, Sahni D. Survival outcomes of mucosal melanoma in the USA. Future Oncol. 2019 Dec; 15(34):3977-3986. PMID: 31724885.
Read at: PubMed - Published on 8/2/2019
Venkatesh S, Al-Haseni A, Sahni D. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab. BMJ Case Rep. 2019 Aug 02; 12(8). PMID: 31377718.
Read at: PubMed - Published on 8/1/2019
Abbott JL, Qureshi MM, Truong MT, Sahni D. Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation. Melanoma Res. 2019 08; 29(4):413-419. PMID: 30383720.
Read at: PubMed - Published on 1/1/2019
Ho JD, Chung HJ, Ms Barron A, Ho DA, Sahni D, Browning JL, Bhawan J. Extensive CD34-to-CD90 Fibroblast Transition Defines Regions of Cutaneous Reparative, Hypertrophic, and Keloidal Scarring. Am J Dermatopathol. 2019 Jan; 41(1):16-28. PMID: 30320623.
Read at: PubMed - Published on 10/3/2018
Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44. PMID: 30281145.
Read at: PubMed - Published on 5/29/2018
Ho JD, Al-Haseni A, Smith S, Bhawan J, Sahni D. Bullous complex regional pain syndrome: A description of the clinical and histopathologic features. J Cutan Pathol. 2018 Aug; 45(8):633-635. PMID: 29704267.
Read at: PubMed - Published on 5/19/2018
Singh B, Qureshi MM, Truong MT, Sahni D. Optimal surgical modality for early Merkel cell carcinoma: Results from the National Cancer Database. J Am Acad Dermatol. 2023 Mar; 88(3):e129-e130. PMID: 29787838.
Read at: PubMed
View 17 more publications: View full profile at BUMC